Floatz logo

Tibulizumab

Systemic Sclerosis (SSc)

Zura Bio Incmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

24 Active assets in the Systemic Sclerosis (SSc) cohort.

View all 41

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →